	US 12,280,088 B2
	Dry powder formulation of caveolin-1 peptides and methods of use thereof
Robert O. Williams, III, Austin, TX (US); Alan B. Watts, Austin, TX (US); Yajie Zhang, Austin, TX (US); Sawittree Sahakijpijarn, Austin, TX (US); Dale Christensen, Austin, TX (US); and John J. Koleng, Austin, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US); and Rein Therapeutics, Inc., Austin, TX (US)
Appl. No. 17/274,666
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US); and REIN THERAPEUTICS, INC., Austin, TX (US)
PCT Filed Sep. 10, 2019, PCT No. PCT/US2019/050349 § 371(c)(1), (2) Date Mar. 9, 2021, PCT Pub. No. WO2020/055824, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/729,010, filed on Sep. 10, 2018.
Prior Publication US 2021/0260150 A1, Aug. 26, 2021
Int. Cl. A61K 38/08 (2019.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 38/10 (2006.01); A61K 45/06 (2006.01); A61P 11/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01)

CPC A61K 38/08 (2013.01) [A61K 9/00 (2013.01); A61K 9/0075 (2013.01); A61K 9/14 (2013.01); A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61P 11/00 (2018.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 2319/10 (2013.01)]

18 Claims

1. A dry powder composition comprising particles,

wherein the particles comprise a peptide consisting of FTTFTVT (SEQ ID NO: 2) or a pharmaceutically acceptable salt thereof,

wherein the particles have a median particle diameter of less than 5 μm,

wherein the dry powder composition does not comprise a pharmaceutically acceptable carrier or excipient; and

wherein the dry powder composition is formulated for use in a dry powder inhaler.